Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x Genomics has the GF Score of 60, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes 10x Genomics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
10x Genomics (MEX:TXG) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
10x Genomics GF Score Related Terms
MEX:TXG vs DOCS, WAY, PRVA: GF Score Comparison
For the Health Information Services subindustry, 10x Genomics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's GF Score distribution charts can be found below:
* The bar in red indicates where 10x Genomics's GF Score falls into.
10x Genomics (MEX:TXG) has a GF Score of 60 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on 10x Genomics and its competitors. This is 11% above median its historical median of 54.00. Over the past decade, 10x Genomics' GF Score has ranged from 9.00 to 84.00.
Is 10x Genomics' GF Score too high?
10x Genomics' current GF Score of 60 is 11% above median its 10-year median of 54.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 84.00. Overall, 10x Genomics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' GF Score compare to DOCS and WAY?
10x Genomics' GF Score of 60 can be compared against companies in the Healthcare Providers & Services industry. Historically, 10x Genomics' own GF Score has ranged from 9.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on 10x Genomics and its competitors. 10x Genomics's current GF Score is 60, which is 11% above median its own 10-year median of 54.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current GF Score of 60. The stock's GF Value™ is MXN145.06, compared to a current price of MXN335.54 — trading 131.3% above its estimated fair value. The current GF Score is 60, which is 11% above median its 10-year median of 54.00. 10x Genomics' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current GF Score is 60 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 131.3% above its estimated GF Value™ of MXN145.06.
Key valuation signals for MEX:TXG:
GF Score: 60 (11% above median its 10-year median of 54.00)
GF Value™: MXN145.06 vs. price of MXN335.54 (131.3% above fair value)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
60GF Score
Get the complete analysis for MEX:TXG
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
